Study Finds Early Biologic Treatment Benefits Crohn's Disease Patients

A new study in The Lancet Gastroenterology & Hepatology indicates that initiating advanced biologic medications early after a Crohn's disease diagnosis significantly improves long-term outcomes. The trial, tracking over 350 patients for five years, found that early "top-down" treatment doubled the likelihood of avoiding disease progression and hospital admissions, and reduced the risk of abdominal surgery five-fold. This research suggests a shift in treatment strategy could greatly benefit patients.